# Cannabis Sales and Use Are High in Michigan – But Federal Law Means Research Lags Behind > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-research-barriers-michigan-impact/ > **Published:** 2026-04-16T21:21:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:20:15-04:00 > **Clinical Summary:** Explore cannabis research barriers Michigan faces due to federal law, impacting clinical practice and patient safety in legal cannabis markets. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchPolicyTHCSafety Why This Matters Clinicians in Michigan and other states with legal cannabis markets face a knowledge gap that directly impacts patient counseling and safety, since federal scheduling restrictions severely limit the [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) available to inform evidence-based recommendations. Without robust research data on efficacy, dosing, drug interactions, and long-term effects, clinicians cannot reliably advise patients on cannabis use for specific conditions or identify which patients are at highest risk for adverse outcomes. Advocating for rescheduling and reduced research barriers is essential for clinicians to transition from anecdotal guidance to evidence-based practice in states where patients already have legal access. Clinical Summary Michigan’s robust cannabis market and high consumer use rates create a natural laboratory for studying cannabis efficacy and safety, yet federal scheduling remains a critical impediment to conducting rigorous clinical research in the state. Even if cannabis is rescheduled from Schedule I to Schedule III, substantial regulatory and logistical barriers will persist, including the need for DEA licensing, restricted research cultivation, and compliance with complex federal protocols that slow study initiation. This research lag means clinicians lack adequate evidence to guide dosing, drug interactions, adverse effect profiles, and appropriate clinical indications despite widespread patient use and commercial availability. The disconnect between state-level legalization and federal prohibition creates a unique challenge where real-world cannabis use outpaces scientific understanding, leaving physicians to counsel patients with incomplete evidence bases. Until federal research barriers are substantially reduced through either rescheduling or dedicated legislative action, clinicians should maintain vigilance for adverse effects and drug interactions while documenting their observations to help fill the evidence gap. Clinicians should counsel patients that despite cannabis’s legal availability in Michigan, the scientific evidence supporting its use remains limited, and they should report adverse effects or unexpected outcomes to their providers. Dr. Caplan’s Take “The disconnect between Michigan’s thriving legal market and our inability to conduct rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) creates a two-tier system where patients get products without the evidence base we’d demand for any other medication, and physicians like me are left practicing without the data we need to optimize dosing and identify which patients truly benefit versus those at risk for harm.” Clinical Perspective The persistent federal scheduling of cannabis creates a significant research gap that directly impacts clinical practice, as Michigan providers must counsel patients on products with incomplete safety and efficacy data despite their legal availability at the state level. The fragmentation between state legalization and federal restrictions means that rigorous, adequately powered clinical trials remain difficult to conduct, leaving providers to extrapolate from limited evidence when addressing questions about drug interactions, optimal dosing, adverse effects, and long-term health consequences. Even if cannabis moves to Schedule III, regulatory hurdles around research design and product standardization will likely persist, meaning providers cannot rely on the same evidence infrastructure available for other therapeutics. Clinicians should therefore adopt a cautious counseling approach that acknowledges both patient autonomy in a legal market and the genuine gaps in our understanding, while documenting their conversations and maintaining vigilance for emerging safety signals in their patient populations. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Cannabis+sales+and+use+are+high+in+Michigan+%E2%80%93+but+federal+law+means+research+lags+behind+%40drcaplan&url=https%3A%2F%2Ftheconversation.com%2Fcannabis-sales-and-use-are-high-in-michigan-but-federal-law-means-research-lags-behind-276731)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Ftheconversation.com%2Fcannabis-sales-and-use-are-high-in-michigan-but-federal-law-means-research-lags-behind-276731)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Cannabis+sales+and+use+are+high+in+Michigan+%E2%80%93+but+federal+law+means+research+lags+behind+--+via+%40drcaplan.bsky.social+https%3A%2F%2Ftheconversation.com%2Fcannabis-sales-and-use-are-high-in-michigan-but-federal-law-means-research-lags-behind-276731)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 230 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-research-digest-march-2026/) 📰 Source: [https://theconversation.com/cannabis-sales-and-use-are-high-in-michigan-but-federal-law-means-research-lags-behind-276731](https://theconversation.com/cannabis-sales-and-use-are-high-in-michigan-but-federal-law-means-research-lags-behind-276731) Further Reading CED Clinic Blog[Cannabis-Infused Creamy Avocado Dip: A Food-First, Dose-Aware Recipe](https://cedclinic.com/cannabis-infused-avocado-dip-recipe/) Research Digest[Research Digest: 4 Recent Studies – April 09, 2026](https://cedclinic.com/4-recent-cannabis-research-studies-april-2026/) Evidence Watch[Nearly 9 in 10 Hospitalized Cannabis Use Disorder Patients Had Medications That Could Potentially Interact With Cannabis](https://cedclinic.com/cannabis-drug-interactions-clinical-evidence-review/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Michigan universities can't study dispensary pot on campus. MSU went mobile](https://cedclinic.com/michigan-universities-cant-study-dispensary-pot-on-campus-msu-went-mobile/) Learn how Michigan universities navigate federal restrictions by adopting mobile research methods for studying cannabis. [Read More](https://cedclinic.com/michigan-universities-cant-study-dispensary-pot-on-campus-msu-went-mobile/) [Does Cannabis Legalization Spur More Innovation Than Medical Research?](https://cedclinic.com/cannabis-innovation-and-medical-research-balance/) Explore the tension between [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) and the pace of [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) in the evolving cannabis landscape. [Explore Insights](https://cedclinic.com/cannabis-innovation-and-medical-research-balance/) Trump’s DOJ Issues New Rescheduling Order – CRB Monitor News Stay updated on federal rescheduling efforts that could impact [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) and clinical practice. Stay Informed ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).